|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0800 - 0.0800|
|52 Week Range||0.0616 - 0.3800|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Announces that it has closed the final tranche of its previously announced non-brokered private placement. ...
BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the final tranche ("Final Tranche") of its previously announced non-brokered private placement (the "Private Placement"). Pursuant to the Final Tranche of the Private Placement, the Company has issued 1,350,000 units ("Units") at a price of $0.10 per Unit for gross proceeds of $135,000. Including the first tranche of the Private Placement which completed on August
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Craig Loverock has joined the Company as Chief Financial Officer. Mr. Loverock is replacing Mr. Lachlan McLeod, who has been the acting CFO following the transition from Lions Bay Mining Inc. to BioVaxys in October 2020. Mr. McLeod will be resuming his full-time duties with Fehr & Associates CPA.